Viking Therapeutics TodayVKTXViking Therapeutics$28.32 -0.88 (-3.01%) 52-Week Range$27.50▼$99.41Price Target$97.29Add to WatchlistThe GLP-1 industry is currently an oligopoly ruled by two pharmaceutical giants, Novo Nordisk A/S NYSE: NVO, maker of semaglutide under the Ozempic and Wegovy name brands, and Eli Lilly & Co. NYSE: LLY, maker of tirzepatide and dual GLP-1/GIP agonist treatment sold under Mounjaro and Zepbound name brands. As compounding facilities cease making compounded versions of their drugs, ...